Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | CDC42 | P60953 | 1/20 | 0.43 |
| ▸ | RAC1 | P63000 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CPS1 | P31327 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347876 | 0.87 | PTGS2 (0.45) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL24223271 | 0.85 | FFAR4 (0.41) | — | |
| SCHEMBL5041933 | 0.82 | ALDH1A1 (0.38) | AKR1C3AKR1C2PTGS2KDM4E | |
| SCHEMBL5041566 | 0.81 | ALDH1A1 (0.50) | KDM4ELDHA | |
| SCHEMBL9862302 | 0.79 | CA12 (0.46) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL5037803 | 0.79 | NPC1 (0.50) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL5041168 | 0.78 | IDO1 (0.46) | AKR1C3AKR1C2CYP1A2TSHRAPP | |
| SCHEMBL5038071 | 0.77 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL5042406 | 0.77 | LMNA (0.41) | PTGS2TSHRLDHA | |
| SCHEMBL5037418 | 0.76 | ALDH1A1 (0.51) | MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222645-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8008503-B2 | Methyl-benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100331371-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | BENSON GREGORY MARTIN | 2010-12-30 | — | — | US | disclosed |
| US-7825258-B2 | Methyl-benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2222645-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009062874-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-05-21 | — | — | US | disclosed |
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | AKR1C3 2566/4885AKR1C2 3493/4885PTGS2 3734/4885 |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | AKR1C3 1423/4885AKR1C2 1700/4885PTGS2 1040/4885 |
| US-20100331371-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | AKR1C3 1423/4885AKR1C2 1700/4885PTGS2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.